US 10,376,584 B2
Stable pharmaceutical formulations of methylnaltrexone
Suketu P. Sanghvi, Kendall Park, NJ (US); and Thomas A. Boyd, Grandview, NY (US)
Assigned to Progenics Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Progenics Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Mar. 30, 2017, as Appl. No. 15/474,614.
Application 15/474,614 is a continuation of application No. 14/039,866, filed on Sep. 27, 2013, granted, now 9,669,096.
Application 14/039,866 is a continuation of application No. 12/639,892, filed on Dec. 16, 2009, abandoned.
Application 12/639,892 is a continuation of application No. 10/821,811, filed on Apr. 8, 2004, abandoned.
Claims priority of provisional application 60/461,611, filed on Apr. 8, 2003.
Prior Publication US 2017/0258911 A1, Sep. 14, 2017
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/02 (2006.01); A61K 31/047 (2006.01); A61K 31/195 (2006.01); A61K 9/19 (2006.01); A61K 45/06 (2006.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 9/00 (2006.01); A61K 31/485 (2006.01)
CPC A61K 47/02 (2013.01) [A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 31/047 (2013.01); A61K 31/195 (2013.01); A61K 31/485 (2013.01); A61K 45/06 (2013.01); A61K 47/12 (2013.01); A61K 47/18 (2013.01); A61K 47/183 (2013.01)] 15 Claims
 
1. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof and a chelating agent; wherein the chelating agent is ethylenediaminetriacetic acid (EDTA) or a derivative thereof.